Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse

Chemotherapy is a standard treatment for pediatric acute lymphoblastic leukemia (ALL), which sometimes relapses with chemoresistant features. However, whether acquired drug-resistance mutations in relapsed ALL pre-exist or are induced by treatment remains unknown. Here we provide direct evidence of...

Celý popis

Podrobná bibliografie

Vydáno v:	Nature cancer Ročník 2; číslo 8; s. 819 - 834
Hlavní autoři:	Yang, Fan, Brady, Samuel W., Tang, Chao, Sun, Huiying, Du, Lijuan, Barz, Malwine J., Ma, Xiaotu, Chen, Yao, Fang, Houshun, Li, Xiaomeng, Kolekar, Pandurang, Pathak, Omkar, Cai, Jiaoyang, Ding, Lixia, Wang, Tianyi, von Stackelberg, Arend, Shen, Shuhong, Eckert, Cornelia, Klco, Jeffery M., Chen, Hongzhuan, Duan, Caiwen, Liu, Yu, Li, Hui, Li, Benshang, Kirschner-Schwabe, Renate, Zhang, Jinghui, Zhou, Bin-Bing S.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.08.2021
Témata:	Chemotherapy Child Cloning Humans Mutagenesis Mutation Neoplastic Syndromes, Hereditary Pediatrics Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Primary Immunodeficiency Diseases Recurrence Tumor Suppressor Protein p53 - genetics Tumors United States > US
ISSN:	2662-1347, 2662-1347
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!